Researchers at the Vall d’Hebron Institute of Oncology (VHIO), part of the Vall d’Hebron Campus, have found that breast milk…
featured news
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that represents about 15% of breast cancer cases. Classified as…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Published in the journal Clinical Cancer Research (1), preliminary results of a two-part, phase I first-in-human study show encouraging antitumor…
Mutations in the TP53 tumor suppressor gene occur in 50% of lung adenocarcinoma and associate with a poor prognosis, but…
Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…
We are delighted to announce that VHIO’s Rodrigo Dienstmann has been appointed as Editor-in-Chief of the European Society for Medical…
Recently published open access in the journal Nature Communications*, an invited Comment article first authored by VHIO’s Elena Garralda, sets…
Blood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial…
VHIO has participated in this project coordinated by INCLIVA, which has made it possible to expand knowledge about this type…
